TransCode Therapeutics, Inc.
TransCode Therapeutics, Inc.
Your view on RNAZ
Overview
What the company does, where it operates, and who runs it.
About TransCode Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Philippe P. Calais Pharm.,
- Headquarters
- 6 Liberty Square, Boston, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Philippe P. Calais Pharm.,
- Headquarters
- 6 Liberty Square, Boston, MA, US
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer.
The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B.
Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells.
The company was incorporated in 2016 and is based in Boston, Massachusetts.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for TransCode Therapeutics, Inc., and the rating behind it. RNAZ last traded at $1.69; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for TransCode Therapeutics, Inc.. Starting points for TransCode Therapeutics, Inc.: EPS -$45.65, beta 1.17 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for TransCode Therapeutics, Inc.. TransCode Therapeutics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for TransCode Therapeutics, Inc.. Trailing twelve-month EPS for TransCode Therapeutics, Inc. stands at -$45.65. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for TransCode Therapeutics, Inc.. TransCode Therapeutics, Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
TransCode Therapeutics, Inc. valued side by side against its closest peers. TransCode Therapeutics, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold TransCode Therapeutics, Inc., and how their positions are changing. At a $1.8M market value, institutional positions materially move TransCode Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by TransCode Therapeutics, Inc. executives and directors. Shares of TransCode Therapeutics, Inc. have traded between $6.15 and $468.44 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming TransCode Therapeutics, Inc.. TransCode Therapeutics, Inc. is a $1.8M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming TransCode Therapeutics, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for TransCode Therapeutics, Inc.. Coverage tracks TransCode Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.